# Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

> **NCT01565889** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 52 (actual)

## Conditions studied

- Hepatitis C
- HIV

## Interventions

- **DRUG:** SOF
- **DRUG:** EFV/FTC/TDF
- **DRUG:** EFV
- **DRUG:** ZDV/3TC
- **DRUG:** ATV
- **DRUG:** Ritonavir
- **DRUG:** FTC/TDF
- **DRUG:** DRV
- **DRUG:** RAL
- **DRUG:** PEG
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01565889
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565889, "Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01565889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*